Login to Your Account

Pain v. Survival

The Prostate Cancer Puzzle: Fitting the Players into Place

By Trista Morrison

Monday, November 7, 2011

Medivation Inc.'s strong Phase III survival data for prostate cancer drug MDV-3100 raise two questions. First, can the prostate cancer market support so many players? And second, with the bar for survival edging higher, is there a place for Phase III prostate cancer trials with alternate endpoints, like Exelixis Inc.'s pain-focused study of cabozantinib?

Analysts say yes on both counts.

While many prostate cancer drugs are starting to come onto the market, they are largely targeting different stages of the disease.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription